Clinical Trials on Moderate to Severe Glabellar Lines in Australia
Total 38 results
-
Medy-ToxCompletedGlabellar Frown LinesAustralia
-
Croma-Pharma GmbHCompleted
-
Medy-ToxCompletedGlabellar Frown LinesAustralia
-
IpsenCompletedGlabellar LinesAustralia, Brazil, Czechia, Kazakhstan, Lebanon, Russian Federation, Turkey, Ukraine
-
KoBioLabsNovotech (Australia) Pty LimitedCompletedModerate to Severe AsthmaAustralia
-
Merz Pharmaceuticals GmbHCompletedGlabellar Frown LinesUnited Kingdom, Germany, Austria
-
AllerganCompletedGlabellar LinesUnited States, Canada, Brazil, France, Australia
-
Sun Pharmaceutical Industries LimitedActive, not recruitingChronic Plaque Psoriasis | Moderate to Severe Nail PsoriasisUnited States, Australia
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessAustralia, Canada, United Kingdom
-
Jiangsu HengRui Medicine Co., Ltd.CompletedModerate-to-severe Chronic Plaque PsoriasisUnited States, Australia, China
-
Kythera BiopharmaceuticalsCompletedPhase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)Moderate or Severe Submental FullnessUnited Kingdom, Canada, Australia
-
Novartis PharmaceuticalsCompletedModerate to Severe Nail PsoriasisGermany, Belgium, Spain, United States, Australia, United Kingdom, Denmark, Czechia, Greece
-
Bausch Health Americas, Inc.TerminatedModerate to Severe Plaque PsoriasisUnited States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
-
AbbVie (prior sponsor, Abbott)CompletedModerate to Severe Plaque PsoriasisUnited States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
-
Novartis PharmaceuticalsCompletedModerate to Severe Palmoplantar PsoriasisBelgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland
-
Novartis PharmaceuticalsCompletedModerate to Severe Plaque-type PsoriasisGermany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
-
Novartis PharmaceuticalsCompletedModerate to Severe Plaque-type PsoriasisUnited States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
Novartis PharmaceuticalsCompletedModerate to Severe Chronic Plaque-Type PsoriasisUnited States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Humanigen, Inc.CompletedModerate-to-Severe AsthmaFrance, United Kingdom, United States, Australia, Poland, Ukraine
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
Delenex Therapeutics AGCompletedMild-to-moderate Psoriasis VulgarisAustria, Germany
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
Hoffmann-La RochePfizerCompletedModerate to Severe Ulcerative ColitisUnited States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
-
Suzhou Connect Biopharmaceuticals, Ltd.CompletedModerate-to-severe Atopic DermatitisUnited States, Australia, China, New Zealand
-
Galderma R&DCompletedModerate-to-Severe Atopic DermatitisUnited States, Australia, Austria, Canada, Czechia, Germany, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Spain, United Kingdom
-
Novartis PharmaceuticalsCompletedModerate and Severe Plaque PsoriasisUnited States, Argentina, Germany, Belgium, Italy, United Kingdom, Turkey, Guatemala, Australia
-
Galderma R&DActive, not recruitingModerate-to-Severe Atopic DermatitisUnited States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, United Kingdom
-
Nektar TherapeuticsRecruitingModerate to Severe Atopic DermatitisUnited States, Australia, Canada
-
UCB Biopharma SRLCompletedPsoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
-
UCB Biopharma SRLCompletedPsoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and Development; Horizon...RecruitingSevere Combined Immunodeficiency Due to RAG1 DeficiencySpain, Netherlands, Italy, Poland, Australia, Turkey, United Kingdom
-
Cognition TherapeuticsNational Institute on Aging (NIA)Active, not recruitingMild to Moderate Alzheimer's DiseaseUnited States, Australia, Netherlands, Czechia, Spain
-
PharmatrophiX Inc.National Institute on Aging (NIA)CompletedMild to Moderate Alzheimer's DiseaseSpain, Germany, Austria, Czechia, Sweden
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine